WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 1-December 2016 (data as of 18-November-2016)
Next overall update June 2017
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 4'8701 Infant (under 12 months) mortality rate: 212
GDP / capita (US$): 14'6871 Child (under 5 years) mortality rate: 242

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 39'667  38'934  38'186  37'439  36'717  31'184  25'912  19'338 
Births 936  944  944  936  919  610  832  839 
Surviving infants 910  917  916  907  890  586  790  763 
Pop. less than 5 years 4'590  4'531  4'441  4'306  4'112  3'088  3'994  3'528 
Pop. less than 15 years 11'320  10'982  10'650  10'341  10'059  10'687  11'230  8'948 
Female 15-49 years 10'711  10'646  10'567  10'474  10'369  8'341  5'935  4'185 

Number of reported cases

(Click for retrospective incidence data for Algeria)
Diphtheria
ChartChart
  30  116 
Japanese encephalitis
ChartChart
 
Measles
ChartChart ChartChart
  63  25  18  112  1'796  15'527 
Mumps
ChartChart
  67  27 
Pertussis
ChartChart
  69  104  23  710 
Polio*
ChartChart
  116 
Rubella
ChartChart
  414  420  170 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
  27 
Tetanus (total)**
ChartChart
  38  86 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Algeria)
Vaccine year result method % card seen                                                
BCG 2011  98  MICS   92  99*  99*  99*  99*  99*  65 
DTP1 2011  97  MICS   92  99*  99*  99*  99*  99* 
DTP3 2011  91  MICS   92  95  95  95  95  95  58 
DTP4          95  95 
IPV1          99* 
HepB_BD          99*  99*  99*  99*  99* 
HepB3 2011  89  MICS   92  95  95  95  95  95 
Hib3 2011  91  MICS   92  95  95  95  95  95 
JapEnc         
MCV1          95  95  95  95  95  80  53 
MCV2          99*  99*  93  95  96 
PCV1         
PCV3         
Pol3 2011  91  MICS   92  95  95  95  95  95  81 
Rota1         
RotaC         
RCV1         
TT2plus 2011  33  MICS   92 
PAB         
VAD1         
YFV         
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2017

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Algeria)
BCG
ChartChart
  99  99  99  99  99  97  99 
DTP1
ChartChart
  99  99  99  99  99  95  96 
DTP3
ChartChart
  95  95  95  95  95  86  89 
HepB3
ChartChart
  95  95  95  95  95 
HepB_BD
ChartChart
  99  99  99  99  99 
Hib3
ChartChart
  95  95  95  95  95 
IPV1
ChartChart
 
MCV1
ChartChart
  95  95  95  95  95  80  83 
MCV2
ChartChart
  99  99  93  95  96  78 
PAB
ChartChart
  92  92  90  90  90  64  75 
PCV3
ChartChart
 
Pol3
ChartChart
  95  95  95  95  95  86  89 
RCV1
ChartChart
 
RotaC
ChartChart
 

Number of districts in the country 271  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
98 
   
/
|
|
\
Greater or equal to 90% 10
From 80 to 89% 7
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
83
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth;
DT 6 years;
DTwPHib 3, 4, 5, 18 months;
HepB birth; 1, 5 months;
IPV 3 months;
Influenza >=65 years; Yes Elderly with chronic illness, pregnant women, health workers, Haj and other travellers, and other risk groups
Measles 9 months; 6 years;
OPV birth; 3, 4, 5, 18 months; 6 years; Yes
Td 11-13, 16-18 years;

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  Yes  Yes  Yes  Yes    Yes 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number 271  271         

System performance

Total Nº districts in country number 271  271  271  271  271  271  464 
Nº districts with DTP3 coverage >=80% number 48        44  193   
% of districts with DTP3 coverage >=80% From 0 to 100% 18        16  71   
Nº districts with measles (MCV1) coverage >=95% number 21        81   
% of districts with MCV1 coverage >=95% From 0 to 100%       30   

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes    Yes   
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes    Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100% 100  100  100      100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes   

Sources

 1  "The 2016 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.